What are the recommended antibiotics for treating Pseudomonas aeruginosa infection in adults?

Antibiotics for Pseudomonas aeruginosa Infections

For definitive treatment of Pseudomonas aeruginosa infections, base your antibiotic choice on antimicrobial susceptibility testing results, using monotherapy with a susceptible agent for stable patients and combination therapy only for those in septic shock or at high risk of death (mortality risk >25%). 1

Treatment Algorithm Based on Clinical Severity

Stable Patients (Not in Septic Shock, Mortality Risk <15%)

Once susceptibility results are available:

• Use monotherapy with any susceptible antipseudomonal agent 1
• Never use aminoglycoside monotherapy - this is strongly contraindicated regardless of susceptibility 1
• Acceptable monotherapy options when susceptible include:
  • Antipseudomonal beta-lactams (piperacillin-tazobactam, ceftazidime, cefepime, carbapenems)
  • Fluoroquinolones (ciprofloxacin, levofloxacin)
  • Newer agents (ceftolozane-tazobactam, ceftazidime-avibactam)

Critically Ill Patients (Septic Shock or Mortality Risk >25%)

• Use combination therapy with 2 susceptible antibiotics until septic shock resolves 1
• Once shock resolves, de-escalate to monotherapy
• Still avoid aminoglycoside monotherapy, but aminoglycosides can be used as part of combination therapy

Specific Clinical Scenarios

Hospital-Acquired/Ventilator-Associated Pneumonia

For suspected Pseudomonas in severe CAP or HAP/VAP 2:

• Empiric therapy: Piperacillin-tazobactam or carbapenem PLUS ciprofloxacin (or levofloxacin), OR beta-lactam with aminoglycoside and azithromycin
• For MDR strains susceptible only to aminoglycosides/polymyxins: Use both inhaled and systemic antibiotics rather than systemic alone 1

Multidrug-Resistant (MDR) Pseudomonas

Recent evidence suggests a hierarchy for newer agents 3, 4, 5:

1. First-line for MDR: Ceftolozane-tazobactam or ceftazidime-avibactam

   • Ceftolozane-tazobactam preferred specifically for pneumonia 4
   • Either can be used for other infection types 4

2. Second-line when resistance develops: Imipenem-relebactam or cefiderocol (when metallo-beta-lactamases absent) 4, 5

3. For metallo-beta-lactamase producers: Cefiderocol is the preferred agent 4, 5

   • Alternative: Aztreonam-avibactam or ceftazidime-avibactam combined with aztreonam
   • Polymyxins combined with meropenem (limited evidence)

Critical Pitfalls to Avoid

Never use aminoglycoside monotherapy - this carries a strong recommendation against it even when the organism is susceptible 1. The evidence shows this approach is inferior for mortality and clinical outcomes.

Do not continue combination therapy after shock resolves - once a patient's septic shock has resolved and you have susceptibility data, de-escalate to monotherapy to reduce toxicity and resistance pressure 1.

Avoid empiric use of newer agents when not needed - reserve ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol for confirmed MDR/XDR infections or high-risk patients to preserve these agents 5, 6.

Adjunctive Inhaled Therapy

For VAP with gram-negative bacilli (including Pseudomonas) susceptible only to aminoglycosides or polymyxins, add inhaled antibiotics to systemic therapy rather than using systemic alone 1. This can also be considered as salvage therapy for patients failing IV antibiotics alone, regardless of resistance pattern 1.

Combination Therapy Controversy

Despite in vitro synergy data, there is no clinical evidence supporting routine combination therapy for difficult-to-treat Pseudomonas infections outside of septic shock 4. The guidelines only recommend combination therapy for the specific high-mortality scenarios described above, not as a general strategy.